Mandate

Acquisition of Lideta Hälsovård

November 10, 2017 M&A

Vinge is advising Nordstjernan in conjunction with the acquisition of a majority of the shares in Lideta Hälsovård.

Lideta conducts primary care via 15 centres in Stockholm and in southern Sweden. The company has grown quickly since it was founded in 2001 by doctor Simon Larsson and currently has 93 000 listed patients, 350 employees and a turnover of approximately MSEK 500.

The transaction is conditional upon approval by the relevant competition authorities, which is expected during the fourth quarter of 2017.

Vinge’s team consisted of partners Johan Winnerblad and Kristina Ekberg, associates Samra Baytar, Johanna Wiberg and Marion Kronberg. Grant McKelvey and Xandra Ståhlberg provided competition law advice.

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024